A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (Explores What the Body Does to the Drug), and Pharmacodynamics (Explores What a Drug Does to the Body) of JNJ-38431055 in Volunteers With Type 2 Diabetes Mellitus

NCT00871507 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

25

Enrollment

INDUSTRY

Sponsor class

Conditions

Diabetes Mellitus, Type 2

Interventions

DRUG: JNJ-38431055 Dose 1
DRUG: Sitagliptin 100 mg
DRUG: Placebo
DRUG: JNJ-38431055 Dose 2

Sponsor

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.